Key Takeaways AIT's Engineered Solutions segment grew 13.5% in Q3, fueled by tech, automation and fluid power demand. Acquisitions of IRIS and Hydradyne expanded automation and boosted Southeast U.S. market presence. Distribution segment weakness and rising SGApplied Industrial Technologies, Inc. (AIT) is witnessing strength across its served markets of technology, food & beverage, pulp & paper and transportation. Solid momentum in the technology-related fluid power market is driving the Engineered Soluti ...

Core Insights - Applied Industrial Technologies, Inc. (AIT) is positioned for growth with strong performance in key markets such as technology, food & beverage, pulp & paper, aggregates, and transportation [1] - The Engineered Solutions segment saw a revenue increase of 13.5% year over year in Q3 FY25, driven by technology-related fluid power demand [1][7] Acquisitions and Market Expansion - AIT is focused on enhancing its capabilities through acquisitions, which positively impacted sales by 6.6% in the fiscal third quarter [2] - Recent acquisitions include IRIS Factory Automation and Hydradyne, which have strengthened AIT's automation and fluid power offerings, respectively [2] - The acquisition of Grupo Kopar in May 2024 expanded AIT's automation platform into Mexico [2] Shareholder Returns - AIT has committed to rewarding shareholders with dividends and share buybacks, paying out $46.2 million in dividends in the first nine months of fiscal 2025, an increase of 11.2% year over year [3] - A quarterly dividend rate hike of 24% was implemented in January 2025 [3] - A new share buyback program was authorized in April 2025 to repurchase up to 1.5 million shares [4] Financial Performance - AIT's stock has gained 20.9% over the past year, outperforming the industry growth of 4.2% [5] - The Service Center revenues fell by 3.5% in Q3 FY25 due to weak MRO and local account sales [7][8] - SG&A expenses increased by 4.1% year over year in Q3 FY25, reaching 19.4% of total revenues [9]

Core Insights - Ginkgo Bioworks has made significant progress in its restructuring efforts, targeting $250 million in cost savings by Q3 2025 [1][3][7] - The company reported a total revenue of $48 million for Q1 2025, a 27% increase from $38 million in the same period last year, primarily due to a $7 million non-cash revenue release [6][22] - Ginkgo's Solutions business is becoming a trusted R&D service provider for the US Government and biopharma industry, while its Tools business is gaining traction in AI-related opportunities [3][7] Financial Performance - Q1 2025 total revenue was $48 million, with $31 million from Cell Engineering (up 10% year-over-year) and $10 million from Biosecurity (flat year-over-year) [6][22] - The company reported a GAAP net loss of $91 million for Q1 2025, an improvement from a net loss of $166 million in the prior year [6][22] - Adjusted EBITDA for Q1 2025 was $(47) million, an improvement from $(117) million in the prior year, driven by increased revenue and reduced operating expenses [6][22] Strategic Positioning - Ginkgo is well-positioned in the biotechnology sector, with 28 US Government projects and a contracted backlog of approximately $180 million [7] - The company is focusing on biosecurity and R&D services, which are deemed critical by national policy reports [7] - Ginkgo's Datapoints and Automation offerings are generating new deals, including a recent agreement with Aura Genetics [7] Guidance and Outlook - Ginkgo has updated its 2025 guidance to reflect total revenue expectations of $160-$180 million, with Cell Engineering revenue projected at $110-$130 million and Biosecurity revenue at least $50 million [5][13] - The company aims to achieve Adjusted EBITDA breakeven by the end of 2026 [7]